# Zantac (ranitidine) & cancer risk

> NDMA contamination in ranitidine products and cancer allegations after market withdrawal.

**Canonical URL:** https://drugsmonitor.com/injuries/zantac-cancer
**Last updated:** 2026-06-11

**Related cases:** https://drugsmonitor.com/case/zantac-ranitidine-lawsuit

Ranitidine (Zantac) was withdrawn after NDMA impurity concerns. Plaintiffs allege various cancers after long-term use; scientific and legal causation remains contested.

Federal MDL proceedings have addressed generic manufacturer preemption and personal jurisdiction issues.

Pharmacy fill history and cancer diagnosis dates are frequently reviewed.

---

*Educational injury overview. Not medical advice.*